Scholarlink

Abstract <p>We aimed to assess whether leukocyte telomere length could serve as a non-invasive biomarker for carcinoma in situ (CIS) of the bladder. Genomic DNA was isolated from peripheral whole blood samples and telomere length was therefore considered to reflect leukocyte telomere length. 37 bladder cancer patients and 37 age-matched healthy controls were enrolled to this study. Relative telomere length was measured using quantitative PCR, and associations with clinical outcomes were evaluated. Bladder cancer patients had significantly shorter telomeres than both age-matched (<i>p</i> = 0.0006) and unmatched controls (<i>p</i> = 0.0028). Carcinoma in situ cases exhibited the shortest telomeres, with levels significantly lower than both controls and non-CIS bladder cancer cases (<i>p</i> &lt; 0.0001 and <i>p</i> = 0.0003, respectively). ROC analysis showed strong discriminatory ability for identifying CIS (AUC = 0.848, <i>p</i> &lt; 0.0001; CI: 0.692–0.944). Importantly, no patient with long telomeres experienced recurrence, while shorter telomeres were associated with higher recurrence risk. These findings indicate that peripheral blood telomere length may serve as both a diagnostic and prognostic biomarker in bladder cancer, particularly for CIS. Larger independent cohorts are required to validate its clinical utility.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Leukocyte Telomere Length as a Marker for Differentiating Carcinoma in Situ of the Bladder from Non-Carcinoma In Situ Bladder Tumors

  • 期刊论文

  • 发表日期：

    2026年7月9日

查看全文
  • G. Güllü Amuran,
  • I. Peker Eyüboğlu,
  • B. Polat,
  • Y. E. Genç,
  • H. B. Akay,
  • H. K. Çam,
  • M. Akkiprik

摘要

Abstract

We aimed to assess whether leukocyte telomere length could serve as a non-invasive biomarker for carcinoma in situ (CIS) of the bladder. Genomic DNA was isolated from peripheral whole blood samples and telomere length was therefore considered to reflect leukocyte telomere length. 37 bladder cancer patients and 37 age-matched healthy controls were enrolled to this study. Relative telomere length was measured using quantitative PCR, and associations with clinical outcomes were evaluated. Bladder cancer patients had significantly shorter telomeres than both age-matched (p = 0.0006) and unmatched controls (p = 0.0028). Carcinoma in situ cases exhibited the shortest telomeres, with levels significantly lower than both controls and non-CIS bladder cancer cases (p < 0.0001 and p = 0.0003, respectively). ROC analysis showed strong discriminatory ability for identifying CIS (AUC = 0.848, p < 0.0001; CI: 0.692–0.944). Importantly, no patient with long telomeres experienced recurrence, while shorter telomeres were associated with higher recurrence risk. These findings indicate that peripheral blood telomere length may serve as both a diagnostic and prognostic biomarker in bladder cancer, particularly for CIS. Larger independent cohorts are required to validate its clinical utility.